30,096 Shares in Viking Therapeutics, Inc. $VKTX Bought by Fox Run Management L.L.C.

Fox Run Management L.L.C. bought a new position in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 30,096 shares of the biotechnology company’s stock, valued at approximately $1,059,000.

Other large investors have also added to or reduced their stakes in the company. RFG Advisory LLC lifted its stake in Viking Therapeutics by 84.8% in the third quarter. RFG Advisory LLC now owns 120,214 shares of the biotechnology company’s stock valued at $3,159,000 after acquiring an additional 55,175 shares during the last quarter. Royal Fund Management LLC acquired a new stake in Viking Therapeutics in the fourth quarter valued at $1,518,000. Rafferty Asset Management LLC lifted its stake in Viking Therapeutics by 26.6% in the third quarter. Rafferty Asset Management LLC now owns 199,387 shares of the biotechnology company’s stock valued at $5,240,000 after acquiring an additional 41,888 shares during the last quarter. Baker BROS. Advisors LP acquired a new stake in Viking Therapeutics in the third quarter valued at $9,621,000. Finally, WINTON GROUP Ltd acquired a new stake in Viking Therapeutics in the third quarter valued at $1,805,000. Institutional investors and hedge funds own 76.03% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Morgan Stanley set a $95.00 price target on shares of Viking Therapeutics in a research note on Thursday, April 30th. HC Wainwright reiterated a “buy” rating and issued a $102.00 price target on shares of Viking Therapeutics in a research note on Monday, March 23rd. Zacks Research upgraded shares of Viking Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 18th. BTIG Research reiterated a “buy” rating and issued a $125.00 price target on shares of Viking Therapeutics in a research note on Friday, May 1st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Viking Therapeutics in a research note on Monday, April 20th. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $93.60.

Viking Therapeutics Stock Performance

NASDAQ VKTX opened at $29.23 on Wednesday. The stock has a market cap of $3.39 billion, a PE ratio of -7.06 and a beta of 0.69. The firm has a 50-day moving average of $32.11 and a 200-day moving average of $32.99. Viking Therapeutics, Inc. has a 52-week low of $22.96 and a 52-week high of $43.15.

Viking Therapeutics (NASDAQ:VKTX) last announced its quarterly earnings results on Thursday, April 30th. The biotechnology company reported ($1.37) EPS for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.36). During the same quarter last year, the business posted ($0.41) EPS. As a group, analysts predict that Viking Therapeutics, Inc. will post -4.7 EPS for the current fiscal year.

Viking Therapeutics Profile

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, the company’s pipeline leverages small-molecule approaches to target hormone signaling pathways implicated in conditions such as non‐alcoholic steatohepatitis (NASH), dyslipidemia, type 2 diabetes and muscle wasting disorders.

The company’s lead programs include VK2809, a thyroid hormone receptor‐beta agonist designed to reduce liver fat and improve lipid profiles in patients with NASH and dyslipidemia, and VK5211, a selective androgen receptor modulator (SARM) aimed at enhancing muscle mass and function in individuals with muscle wasting conditions.